Cargando…

Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study

BACKGROUND: Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with poor 5-year overall survival (OS) at 14%. Patients with mRCC to endocrine organs historically have prolonged OS. Pancreatic metastases are uncommon overall, with mRCC being the most common etiology of pancreatic metast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duarte, Cassandra, Hu, Junxiao, Beuselinck, Benoit, Panian, Justine, Weise, Nicole, Dizman, Nazli, Collier, Katharine A., Rathi, Nityam, Li, Haoran, Elias, Roy, Martinez-Chanza, Nieves, Rose, Tracy L., Harshman, Lauren C., Gopalakrishnan, Dharmesh, Vaishampayan, Ulka, Zakharia, Yousef, Narayan, Vivek, Carneiro, Benedito A., Mega, Anthony, Singla, Nirmish, Meguid, Cheryl, George, Saby, Brugarolas, James, Agarwal, Neeraj, Mortazavi, Amir, Pal, Sumanta, McKay, Rana R., Lam, Elaine T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248040/ https://www.ncbi.nlm.nih.gov/pubmed/37304495 http://dx.doi.org/10.1016/j.eclinm.2023.102018

Ejemplares similares

Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
por: Bergerot, Cristiane Decat, et al.
Publicado: (2019)

Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
por: Gan, Chun Loo, et al.
Publicado: (2021)

Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

The Year in Review for Renal Cancer
por: Vaishampayan, Ulka
Publicado: (2020)

The power of meta-analysis in therapeutic decision making for advanced kidney cancer
por: Vaishampayan, Ulka
Publicado: (2019)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Metastasis in renal cell carcinoma: Biology and implications for therapy
por: Gong, Jun, et al.
Publicado: (2016)

Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2018)

Predictors of Cytoreductive Nephrectomy for Metastatic Kidney Cancer in SEER and Metropolitan Detroit Databases
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study
por: Martinez Chanza, Nieves, et al.
Publicado: (2020)

Immunotherapy and Immune Evasion in Prostate Cancer
por: Thakur, Archana, et al.
Publicado: (2013)

Improving continence after prostatectomy: integrating magnetic resonance imaging with the Retzius-sparing approach
por: Singla, Nirmish
Publicado: (2020)

Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Pro
por: Campbell, Steven C., et al.
Publicado: (2022)

Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021)

Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
por: Casadei, Chiara, et al.
Publicado: (2019)

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
por: Rathi, Nityam, et al.
Publicado: (2020)

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019)

Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive
por: Hahn, Andrew W., et al.
Publicado: (2022)

Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048
por: Semrad, Thomas J, et al.
Publicado: (2019)

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
por: Vaishampayan, Ulka, et al.
Publicado: (2015)

Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2022)

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Artificial urinary sphincters for male stress urinary incontinence: current perspectives
por: Cordon, Billy H, et al.
Publicado: (2016)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma
por: Dizman, Nazli, et al.
Publicado: (2020)

Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
por: Rathi, Nityam, et al.
Publicado: (2020)

DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC)
por: Rathi, Nityam, et al.
Publicado: (2018)

Adrenal pheochromocytoma in a patient with Lynch Syndrome
por: Rodriguez, Katherine M., et al.
Publicado: (2022)

Surgical Excision of Duodenal/Pancreatic Metastatic Renal Cell Carcinoma
por: Espinoza, Eduardo, et al.
Publicado: (2014)

Case Report: Immune Checkpoint Inhibitor-Induced Exuberant Tumor Inflammation With Accelerated Clinical Deterioration in Metastatic Renal Cell Carcinoma
por: Gopalakrishnan, Dharmesh, et al.
Publicado: (2021)

Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts
por: Tse, Jennifer, et al.
Publicado: (2019)

Testicular Size Discrepancy in a Man Evaluated for Vasectomy
por: Singla, Nirmish, et al.
Publicado: (2016)

Evaluation of Hematuria in a Large Public Health Care System
por: Ghandour, Rashed, et al.
Publicado: (2019)

Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth
por: Govindarajan, Barani, et al.
Publicado: (2023)

Every decade counts: a narrative review of functional recovery after partial nephrectomy
por: Campbell, Steven C., et al.
Publicado: (2022)

Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival
por: Ramos, Jorge D., et al.
Publicado: (2016)

Corrigendum to ‘‘Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type’’ [EBioMedicine 51 (2020) 102526]
por: Cai, Qi, et al.
Publicado: (2020)

Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States
por: Swami, Umang, et al.
Publicado: (2021)

Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma
por: Bergerot, Cristiane Decat, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_70lmsqtti50n40o45gjh7d739g